Chemistry:Turletricin
From HandWiki
Turletricin (also known as AM-2-19 and SF001) is an experimental antifungal drug based on amphotericin B (AmB) that is engineered to be less toxic to the kidneys.[1][2][3]
Amphotericin B is a polyene that targets fungal ergosterol as well as human cholesterol, which results in kidney damage. Turletricin instead is selective to fungal ergosterol and also draws out fungal ergosterol more effectively. The investigational new drug (IND) application was filed in May 2023. Turletricin received Qualified Infectious Disease Product (QIDP) for invasive aspergillosis and Fast Track designations from the FDA in 2023. It is now under phase I trial.
An oral formulation is currently in the feasibility phase.
References
- ↑ "New antifungal kills without toxic side effects". https://www.science.org/content/article/new-antifungal-kills-without-toxic-side-effects.
- ↑ Maji, Arun; Soutar, Corinne P.; Zhang, Jiabao; Lewandowska, Agnieszka; Uno, Brice E.; Yan, Su; Shelke, Yogesh; Murhade, Ganesh et al. (8 November 2023). "Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal" (in en). Nature 623 (7989): 1079–1085. doi:10.1038/s41586-023-06710-4. ISSN 1476-4687. PMID 37938782. Bibcode: 2023Natur.623.1079M.
- ↑ "Antifungal analog offers reduced toxicity" (in en). Chemical & Engineering News. https://cen.acs.org/biological-chemistry/Antifungal-analog-offers-reduced-toxicity/101/web/2023/11.
 |  |
